Abstract:Recent reports suggest that microRNAs (miRNAs) may serve as prognostic biomarkers in osteosarcoma. Due to osteosarcoma's early metastasis and poor prognosis, it is very important to find novel prognostic biomarkers for improving osteosarcoma's prognosis. Herein we propose a meta-analysis for serum miRNA's prognostic value in osteosarcoma. In this study, the literature available from PubMed, Web of Science, Embase, and Cochrane Library databases was reviewed. The pooled hazard ratios (HRs) with their 95% confidence intervals (CIs) were calculated to evaluate miRNAs prognostic values. A total of 20 studies investigating serum miRNAs were included in this meta-analysis; the initial terminal point of these reports included overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and recurrence-free survival (RFS). For prognostic meta-analyses, the pooled HR for terminal events of higher expression of miRNAs and lower expression of miRNAs were 5.68 (95% CI 4.73–6.82, <i>P</i> < 0.05) and 3.78 (95% CI 3.27–4.37, <i>P</i> < 0.05), respectively. Additionally, subgroup analyses were conducted based on the analysis methods applied and clinicopathological features reported. In the pooled analyses, the miRNA expression levels are associated with poor prognosis according to both univariate and multivariate analyses. Furthermore, serum miRNAs (miRNA-195, miRNA-27a, miRNA-191, miRNA-300, miRNA-326, miRNA-497, miRNA-95-3p, miRNA-223, miRNA-491-5p, miRNA-124, miRNA-101, miRNA-139-5p, miRNA-194) were associated with poor OS and found to be closely correlated with clinical stage and distant metastasis in osteosarcoma. The results illustrate that low or high expression of these specific miRNAs are both potentially useful as prognostic serum biomarkers in osteosarcoma, and miRNAs (miRNA-195, miRNA-27a, miRNA-191, miRNA-300, miRNA-326, miRNA-497, miRNA-95-3p, miRNA-223, miRNA-491-5p, miRNA-124, miRNA-101, miRNA-139-5p, miRNA-194) may indicate clinical stage and metastasis in this form of cancer.

Prognostic Value of Serum Mir-217 Level in Osteosarcoma Patients

Serum Levels of Microrna-133B and Microrna-206 Expression Predict Prognosis in Patients with Osteosarcoma.

Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis

Combined Elevation of Microrna-196A and Microrna-196B in Sera Predicts Unfavorable Prognosis in Patients with Osteosarcomas

Identification of Mir-199a-5p in Serum As Noninvasive Biomarkers for Detecting and Monitoring Osteosarcoma

Clinical Significance Of Tumor Mir-21, Mir-221, Mir-143, And Mir-106a As Biomarkers In Patients With Osteosarcoma

Identification of Serum Mir-337-3p, Mir-484, Mir-582, and Mir-3677 As Promising Biomarkers for Osteosarcoma.

Hsa-miR-557 Inhibits Osteosarcoma Growth Through Targeting KRAS

MicroRNA-145 Downregulation Associates with Advanced Tumor Progression and Poor Prognosis in Patients Suffering Osteosarcoma

Down-regulation of miR-133a and miR-539 are associated with unfavorable prognosis in patients suffering from osteosarcoma

Prognostic Evaluation of Microrna-210 Expression in Pediatric Osteosarcoma

Downregulation of Mir-138 Predicts Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma.

MiR-598: A Tumor Suppressor with Biomarker Significance in Osteosarcoma

MicroRNA-9 expression is a prognostic biomarker in patients with osteosarcoma

MicroRNA-455-3p Inhibits Osteosarcoma Progression Via HSF1 Downregulation

Downregulation of Microrna-15A-3p is Correlated with Clinical Outcome and Negatively Regulates Cancer Proliferation and Migration in Human Osteosarcoma

A Four Serum-Mirna Panel Serves As a Potential Diagnostic Biomarker of Osteosarcoma.

Prognostic Significance of Serum Mir-193 B in Colorectal Cancer

MicroRNA-133a Inhibits Osteosarcoma Cells Proliferation and Invasion Via Targeting IGF-1R

Tumor-Suppressing Effects of Mir-429 on Human Osteosarcoma

Upregulated Expression of Microrna-214 is Linked to Tumor Progression and Adverse Prognosis in Pediatric Osteosarcoma.